---
title: "Lemaitre Vascular | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 64.45 M"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276945636.md"
datetime: "2026-02-25T21:56:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276945636.md)
  - [en](https://longbridge.com/en/news/276945636.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276945636.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/276945636.md) | [English](https://longbridge.com/en/news/276945636.md)


# Lemaitre Vascular | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 64.45 M

Revenue: As of FY2025 Q4, the actual value is USD 64.45 M, beating the estimate of USD 62.82 M.

EPS: As of FY2025 Q4, the actual value is USD 0.68, beating the estimate of USD 0.6636.

EBIT: As of FY2025 Q4, the actual value is USD 16.78 M.

### Q4 2025 Financial Highlights

-   **Sales**: LeMaitre Vascular, Inc. reported sales of $64.5 million, marking a 16% increase (15% organic) compared to Q4 2024 . Net sales for the quarter were $64,453 thousand .
-   **Gross Margin**: Improved by 240 basis points to 71.7% . Gross profit was $46,190 thousand .
-   **Operating Income**: Grew by 47% to $18.8 million . Income from operations was $18,832 thousand .
-   **Operating Margin**: Stood at 29% .
-   **Net Income**: Reached $15,582 thousand .
-   **Operational Costs**: Operating expense growth was moderate at 6% .
-   **Segment Revenue (Geographic)**: Americas contributed $40,169 thousand (62%), Europe, Middle East and Africa $19,691 thousand (31%), and Asia Pacific $4,593 thousand (7%) . Sales growth was primarily driven by Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) . Geographically, EMEA sales increased by 29%, APAC by 20%, and the Americas by 10% .
-   **Unique Metrics**: Adjusted EBITDA for the quarter was $20,857 thousand, an increase of 39% .

### Full Year 2025 Financial Highlights

-   **Sales**: LeMaitre Vascular, Inc. achieved 14% sales growth, with net sales totaling $249,602 thousand .
-   **Gross Profit**: Was $178,539 thousand .
-   **Operating Income**: Grew by 30% to $67,912 thousand .
-   **Net Income**: Was $57,734 thousand .
-   **Segment Revenue (Geographic)**: Americas contributed $159,665 thousand (64%), Europe, Middle East and Africa $73,122 thousand (29%), and Asia Pacific $16,815 thousand (7%) .
-   **Unique Metrics**: Adjusted EBITDA for the year was $74,312 thousand, an increase of 20% . Adjusted earnings per share was $2.38, an increase of 23% from $1.93 in 2024 .

### Balance Sheet Highlights (as of December 31, 2025)

-   **Cash and Cash Equivalents**: $28,244 thousand .
-   **Total Current Assets**: $468,232 thousand, including cash and cash equivalents of $28,244 thousand and short-term marketable securities of $330,876 thousand .
-   **Total Assets**: Amounted to $615,690 thousand .
-   **Total Current Liabilities**: $36,323 thousand .
-   **Total Liabilities**: Were $222,174 thousand .
-   **Total Stockholders’ Equity**: Was $393,516 thousand .

### Cash Flow & Capital Allocation

-   **Cash Position**: Cash increased sequentially by $16.1 million to $359.1 million .
-   **Dividends**: The Board of Directors of LeMaitre Vascular, Inc. approved a 25% increase in the quarterly dividend to $0.25 per share of common stock .
-   **Share Repurchase**: The Board also authorized the repurchase of up to $100.0 million of the company’s common stock .

### Business Outlook / Guidance

For Q1 2026, \[勒梅特微管医疗\] projects sales between $65.6 million and $67.6 million (midpoint $66.6 million, +11%, +10% organic), with operating income between $16.7 million and $18.1 million (midpoint $17.4 million, +38%) and an operating margin midpoint of 26% . For the full year 2026, sales are expected to be between $276 million and $284 million (midpoint $280 million, +12%, +12% organic), with operating income between $75.0 million and $80.7 million (midpoint $77.8 million, +15%, adjusted +21%) and an operating margin midpoint of 28% . This guidance anticipates another year of healthy sales and profit growth for \[勒梅特微管医疗\] .

### 相關股票

- [Lemaitre Vascular (LMAT.US)](https://longbridge.com/zh-HK/quote/LMAT.US.md)

## 相關資訊與研究

- [A LeMaitre Vascular (LMAT) Insider Sold 2,625 Shares for $285K](https://longbridge.com/zh-HK/news/280880388.md)
- [LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of "Moderate Buy" by Brokerages](https://longbridge.com/zh-HK/news/275199312.md)
- [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/zh-HK/news/281530653.md)
- [Cintas (CTAS) Valuation Check After Q3 Results And Higher Fiscal 2026 Guidance](https://longbridge.com/zh-HK/news/281225115.md)
- [Key facts: Bunge Increases Securitization to $2.0B; 8-K on Obligation](https://longbridge.com/zh-HK/news/281659964.md)